<DOC>
	<DOCNO>NCT02382549</DOCNO>
	<brief_summary>This study evaluate whether safe administer helper peptide vaccine dabrafenib trametinib . This study also evaluate effect combination peptide vaccine dabrafenib trametinib immune system . We monitor effect perform test laboratory participant ' blood , lymph node , tumor sample .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Melanoma Helper Peptide Vaccine Plus Dabrafenib Trametinib</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Participants measurable stage IIIB , IIIC , IV melanoma clinical radiological evidence disease . These participant may cutaneous , uveal , mucosal primary melanoma , unknown primary melanoma . Staging must confirm cytological histological examination . Staging cutaneous melanoma base revise AJCC stag system . Participants must eligible treated BRAF inhibitor MEK inhibitor combination . Participants require radiological study define radiologically evident disease . Required study include : Chest CT scan , Abdominal pelvic CT scan , Head CT scan MRI Participants metastatic melanoma available biopsy pretreatment day 22 must consent biopsy . These metastasis may nod , skin , soft tissue , liver , site access needle biopsy , incisional excisional biopsy , without image guidance . Participants brain metastasis eligible follow true : The total number brain metastasis ever ≤ 3 Each brain metastasis must completely remove surgery unresected brain metastasis must treat stereotactic radiosurgery . There evident growth brain metastasis since recent treatment No brain metastasis &gt; 2 cm diameter time registration The recent surgical resection gammaknife therapy malignant melanoma must complete ≥ 1 week ≤ 6 month prior registration . ECOG performance status 0 1 Participants must ability willingness give inform consent Laboratory parameter follow : ANC &gt; 1000/mm3 Platelets &gt; 100,000/mm3 Hgb &gt; 9 g/dL HgBA1c ≤ 7.5 % AST ALT 2.5 x upper limit normal ( ULN ) . Patients know Gilbert 's disease may eligible AST ALT 5 x ULN . Bilirubin 2.5 x ULN Alkaline phosphatase 2.5 x ULN . Creatinine 1.5 x ULN Age 18 year old registration Participants must least two intact ( undissected ) axillary and/or inguinal lymph node basins Participants receive follow medication treatment time within 4 week registration : • Chemotherapy Interferon ( e.g . IntronA® ) Radiation therapy ( Stereotactic radiotherapy , gamma knife , use ≥ 1 week ≤ 6 month prior registration ) Allergy desensitization injection Corticosteroids , administer transdermally , parenterally orally . Inhaled steroid ( e.g . : Advair® , Flovent® , Azmacort® ) permit . Topical corticosteroid acceptable . Growth factor ( e.g . Procrit® , Aranesp® , Neulasta® ) Interleukins ( e.g . Proleukin® ) Any investigational medication Targeted therapy specific mutate BRAF MEK inhibitor HIV positivity evidence active Hepatitis C virus . Participants currently receive nitrosoureas receive therapy 6 week prior registration Participants currently receive checkpoint molecule blockade therapy , receive therapy within 3weeks prior registration . Participants know suspected allergy component vaccine . Participants may vaccinate previously synthetic peptide include protocol . Participants receive vaccination contain agent synthetic peptide include protocol recur administration vaccine eligible enroll 12 week follow last vaccination . Pregnancy . Female participant must breastfeed Participants medical contraindication potential problem complying requirement protocol opinion investigator . Participants classify accord New York Heart Association classification Class III IV heart disease . Participants uncontrolled diabetes , define HgBA1c great 7.5 % . Participants must prior autoimmune disorder require cytotoxic immunosuppressive therapy , autoimmune disorder visceral involvement . Participants active autoimmune disorder require therapy also exclude . Participants another cancer diagnosis , except follow diagnosis allow : squamous cell cancer skin without know metastasis basal cell cancer skin without know metastasis carcinoma situ breast ( DCIS LCIS ) carcinoma situ cervix cancer without distant metastasis treat successfully , without evidence recurrence metastasis 3 year Participants know addiction alcohol drug actively take agent , participant recent ( within 1 year registration ) ongoing illicit IV drug use . Body weight &lt; 110 pound Participants know history glucose6phosphate dehydrogenase deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>peptide</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>trametinib</keyword>
	<keyword>Montanide ISA-51</keyword>
	<keyword>MEKINIST</keyword>
	<keyword>Tafinlar</keyword>
</DOC>